{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:50:47Z","timestamp":1784253047657,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.juro.2006.06.066","type":"journal-article","created":{"date-parts":[[2006,9,4]],"date-time":"2006-09-04T11:12:26Z","timestamp":1157368346000},"page":"1387-1391","source":"Crossref","is-referenced-by-count":52,"title":["Association Between the Dihydrotestosterone Level in the Prostate and Prostate Cancer Aggressiveness Using the Gleason Score"],"prefix":"10.1097","volume":"176","author":[{"given":"Tsutomu","family":"Nishiyama","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ikarashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Niigataken Kouseiren Byori Center, Nagaoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2006.06.066_bib1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2006.06.066_bib2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.276.23.1904","article-title":"Occult prostate cancer in men with low serum testosterone levels","volume":"276","author":"Morgentaler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2006.06.066_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0022-5347(05)67812-3","article-title":"Is low serum free testosterone a marker for high grade prostate cancer?","volume":"163","author":"Hoffman","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pros.10140","article-title":"Association between prostate cancer and serum testosterone levels","volume":"53","author":"Zhang","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2006.06.066_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.ju.0000062674.43964.d0","article-title":"Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy","volume":"169","author":"Massengill","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib6","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/01.ju.0000158040.33531.e7","article-title":"Testosterone as a predictor of pathological stage in clinically localized prostate cancer","volume":"173","author":"Isom-Batz","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib7","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/01.ju.0000181818.51977.29","article-title":"Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy","volume":"174","author":"Teloken","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0090-4295(96)00619-X","article-title":"Serum testosterone\u2014a significant determinant of metastatic relapse for irradiated localized prostate cancer","volume":"49","author":"Zagars","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.06.066_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0022-5347(05)64623-X","article-title":"No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer","volume":"168","author":"Fodstad","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib10","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","article-title":"The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer","volume":"10","author":"Nishiyama","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2006.06.066_bib11","first-page":"41","article-title":"Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma","volume":"157","author":"Iversen","year":"1994","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1016\/j.juro.2006.06.066_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-5347(01)62922-7","article-title":"Influence of radical prostatectomy on serum hormone levels","volume":"160","author":"Miller","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib13","first-page":"4161","article-title":"On the prevention and therapy of prostate cancer by androgen administration","volume":"59","author":"Prehn","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2006.06.066_bib14","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2005.05.025","article-title":"Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy","volume":"23","author":"Freedland","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2006.06.066_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2006.06.066_bib16","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1097\/01.ju.0000181216.71605.38","article-title":"The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer","volume":"174","author":"Andriole","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.06.066_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1464-410X.2005.05375.x","article-title":"Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy","volume":"95","author":"Carver","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.06.066_bib18","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.urology.2005.07.036","article-title":"Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome","volume":"66","author":"Rubin","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.06.066_bib19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/00000478-200407000-00013","article-title":"High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate","volume":"28","author":"Li","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.juro.2006.06.066_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/pros.20154","article-title":"Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease","volume":"63","author":"Ricciardelli","year":"2005","journal-title":"Prostate"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706014467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706014467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2006.06.066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:43:26Z","timestamp":1651196606000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2006.06.066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1016\/j.juro.2006.06.066"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2006.06.066","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}